Bio-Serum Particles (BSPs)™ are the next frontier in the cell-free biologics space. Built to move beyond the limitations and inconsistent terminology of the current exosome market, BSPs represent a broader, more purposeful category of nanoscale biologically derived particles designed around composition, function, and reproducibility rather than hype or inflated particle counts.
At BSP Biologics, the goal is not simply to follow the exosome industry, but to help define what comes next. BSPs are positioned as a next-generation biologic platform that integrates scientific clarity, controlled manufacturing, and real-world product quality into a new category built for the future of regenerative aesthetics, wellness, and advanced biologic care.
Bio-Serum Particles (BSPs)™ are nanoscale, biologically derived components prepared from human biologic sources and designed to support intercellular communication through a diverse spectrum of proteins, lipids, and regulatory nucleic acids.
Typically ranging from approximately 20 to 200 nanometers, BSPs may contain proteins, membrane-associated lipids, microRNAs, messenger RNAs, and other signaling molecules relevant to tissue communication and local biologic coordination.
Rather than defining value through a single vesicle subtype or a trend-driven label, BSPs are defined by the integrity of their biologic cargo, the quality of their source material, and the control applied during manufacturing. This allows BSP Biologics to speak more precisely about product quality, characterization, and biologic relevance than many companies operating under the broad exosome label alone.
The current exosome market often uses one popular term to describe a wide range of extracellular vesicles, conditioned media components, and biologic byproducts. BSPs are designed to advance that conversation.
They occupy the same general nanoscale signaling space as exosomes and other extracellular vesicles, but BSPs are positioned around biologic function, preparation quality, and measurable product attributes rather than marketing language alone. This creates a more future-oriented framework for clinicians, distributors, and partners who want a clearer and more disciplined biologic category.
BSP Biologics is built around defined product quality, controlled manufacturing, and reproducibility rather than inflated counts or vague claims about richness or potency.
In the exosome category especially, high particle counts are often presented as a proxy for product quality, even though those counts may include protein aggregates, membrane fragments, non-vesicular particles, or degraded material.
BSP Biologics takes a different approach. The company focuses on functional extracellular vesicle populations and biologically relevant preparations, with an emphasis on traceability from donor to final product, controlled processing, documented release criteria, and consistency lot to lot. This emphasis on quality systems and scientific discipline is central to the BSP brand identity.
BSP Biologics intends to operate at the leading edge of both the BSP platform and the allogeneic exosome space. Within that strategy, Wharton's jelly-derived exosomes remain an important part of the company's scientific and commercial foundation.
At BSP, Wharton's jelly mesenchymal stromal cell-derived exosomes are manufactured using early-passage WJMSCs, typically limited to three passages, in order to preserve biological quality, potency, and product consistency.
This strategy is based on the understanding that mesenchymal stromal cells undergo biologic changes with extended culture expansion, including altered morphology, reduced proliferative capacity, cellular stress, senescence-associated signaling, and changes in secretory behavior that may affect exosome composition and function.
Because exosomes reflect the physiologic state of their parent cells, controlling the passage number of WJMSCs is a critical manufacturing control for preserving the integrity and biologic relevance of the extracellular vesicle product. BSP Biologics also uses a controlled multi-donor strategy rather than relying entirely on a single donor, helping reduce dependence on one biologic source while supporting broader reproducibility, donor qualification, and supply consistency.
The BSP model is designed around a simple principle: biologic quality matters more than superficial metrics. Particle counts alone do not establish functionality, purity, or relevance.
What matters is whether the preparation is derived from qualified biologic source material, processed under controlled conditions, characterized in a meaningful way, and released against defined quality criteria.
This quality-driven model is intended to support consistency, reliability, and long-term credibility in a market that often struggles with variability and under-characterization.
Approximately 20 to 200 nanometers
Proteins, lipids, microRNAs, messenger RNAs, and related signaling cargo
Human biologic materials, including Wharton's jelly-derived platforms within BSP's allogeneic strategy
Designed to participate in intercellular communication and biologic signaling relevant to tissue function and homeostasis
The future of this category will not belong to the companies with the loudest claims. It will belong to those that combine biologic innovation with scientific clarity, manufacturing rigor, and reproducible quality.
BSPs are intended to define that next step by giving the market a more disciplined framework for describing and delivering nanoscale biologic signaling products.
With both BSPs and Wharton's jelly-derived exosomes in its platform, BSP Biologics is positioned not just to participate in the exosome category, but to help lead what comes after it: better-defined, better-characterized, and more biologically meaningful cell-free products built for the next frontier.
Learn MoreTo place an order for Wharton's Jelly-Derived Bio-Serum Particles, scan the QR code below or fill out our form using the link provided.
Scan to order
Complete our online form to place an order. Our team will respond promptly to guide you through the process.
Open Order FormYou can also reach us directly at regenorders@bspbiologics.com